Oncolytics Biotech Inc T.ONC

Roche's oral selective oestrogen degrader fails in BC

[Noteable]

April 25, 2022 - Roche’s previous claims that its oral selective oestrogen degrader giredestrant could be best in class have come to nothing. The group disclosed during its first-quarter results [ on Monday ] that the agent had failed the phase 2 Acelera trial in previously treated ER-positive Her2-negative breast cancer.

https://www.evaluate.com/vantage/articles/news/trial-results/roche-has-rare-breast-cancer-setback

[Noteable]

Roche's April 22, 2022 announcement that it's oral selective estrogen receptor protein degrader giredestrant has come to nothing follows Pfizer's July 22, 2021 announcement that the New York company had partnered with the Phase1/2 company Arvinas to develop their estrogen receptor protein degrader ARV-471 - suggesting that the this collaboration will have a hard hill to climb

[Noteable]

In 2021 Roche also announced that the Swiss company would be walking away from its gene therapy collaboration with 4D Molecular Therapeutics (4DMT) because of product safety issues, and this is of particular interest since Pfizer had taken an equity stake in the company in 2016, prior to Pfizer's Covid-19 windfall.   [ This is another example why pelareorep's safety and

[Noteable]

In 2016 Pfizer also took a 50% equity stake in the OV company Ignite Immunotherapy, which apparently does not exist any longer, and like 4DMT, was another David Kirn company https://www.fiercepharma.com/vaccines/pfizer-backs-cancer-vaccine-startup-ignite-immunotherapy https://4dmoleculartherapeutics.com/people/david-h-kirn-md/

[Buckhenry]

oncy has been going for over 20 years and has produced a big fat goose egg..... and your point here because you think they have something yet their stock price is still in the lower abyss

[Noteable]

August 22, 2022 - Sanofi is stopping development of its oral selective estrogen receptor degrader (SERD) amcenestrant. A failed phase 3 interim analysis dealt the death blow to the program, which Sanofi once saw as the future “endocrine backbone therapy” in breast cancer. https://www.fiercebiotech.com/biotech/sanofi-scraps-oral-serd-after-second-failure-breast-cancer